Zomedica Corp.

$0.10-0.21%($-0.00)
TickerSpark Score
54/100
Mixed
67
Valuation
40
Profitability
50
Growth
84
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZOM research report →

52-Week Range46% of range
Low $0.02
Current $0.10
High $0.20

Companywww.zomedica.com

Zomedica Corp. , a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.

CEO
Larry C. Heaton II
IPO
2017
Employees
144
HQ
Ann Arbor, MI, US

Price Chart

-57.68% · this period
$0.18$0.11$0.03Apr 01Sep 30Apr 01

Valuation

Market Cap
$95.35M
P/E
-4.22
P/S
2.78
P/B
0.86
EV/EBITDA
-3.88
Div Yield
0.00%

Profitability

Gross Margin
66.29%
Op Margin
-71.97%
Net Margin
-65.78%
ROE
-19.16%
ROIC
-21.56%

Growth & Income

Revenue
$32.03M · 17.39%
Net Income
$-81,858,000 · -74.23%
EPS
$-0.08 · -66.67%
Op Income
$-84,353,000
FCF YoY
41.99%

Performance & Tape

52W High
$0.20
52W Low
$0.02
50D MA
$0.11
200D MA
$0.13
Beta
1.16
Avg Volume
8.54M

Get TickerSpark's AI analysis on ZOM

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 17, 25Rowe Jeffrey Mbuy731,368
Mar 17, 25Rowe Jeffrey Mbuy34,725
Mar 17, 25Rowe Jeffrey Mbuy4,265
Mar 17, 25Rowe Jeffrey Mbuy68,000
Mar 17, 25Rowe Jeffrey Mbuy100,647
Mar 17, 25Rowe Jeffrey Mbuy500,000
Mar 17, 25Williams Rodney Jamesbuy100,000
Mar 17, 25Jordan Scottbuy300,000
Mar 17, 25Rowe Jeffrey Mbuy34,725
Mar 17, 25Rowe Jeffrey Mbuy4,265

Our ZOM Coverage

We haven't published any research on ZOM yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate ZOM Report →

Similar Companies